Promopharm warns of 74 percent profit drop. Promopharm stock trails its high by 6.86 percent

Published on 10/14/2026 at 05:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached MAD 507.00 million, up 9.00 percent year over year. Promopharm stock sits 6.86 percent below its 52-week high.

Earnings pressure and market context

Promopharm projected first-half 2026 net income of MAD 6.70 million on September 25, 2026.
First-half revenue reached MAD 507.00 million, up 9.00 percent year over year.
Promopharm ended the week at MAD 1,480.00 on October 12, 2026.

DWY, MA0000011660, Illustration mit AI erstellt.

Promopharm (MA0000011660) projected first-half 2026 net income of MAD 6.70 million on September 25, 2026, down from MAD 26.20 million a year earlier, according to Alphabourse. Promopharm stock was quoted at MAD 1,480.00 on October 13, 2026, 6.86 percent below its 52-week high of MAD 1,589.00.

What weighed on earnings?

Dirham Digest reported on September 30, 2026, that first-half revenue rose to MAD 507.10 million from MAD 464.20 million, a 9.00 percent increase. Net income fell to MAD 6.80 million from MAD 26.30 million, while operating profit declined to MAD 25.60 million from MAD 41.60 million.

The operating margin fell to 5.00 percent from 9.00 percent in the first half of 2026, according to Dirham Digest. Additional depreciation followed the commissioning of Promopharm's injectable-products plant at the end of 2025, while research and development costs increased for new products.

Three dates frame the stock

On September 18, 2026, Promopharm closed at MAD 1,480.00 after trading at MAD 1,379.00 on September 11, a 7.32 percent rise, according to TelQuel. The September 25 warning then put the earnings decline at the center of the investment case, while the September 30 results publication supplied the reported comparison.

On October 12, 2026, TelQuel described Promopharm as unchanged at MAD 1,480.00 for the week covering October 5 through October 9. The contrast is clear: sales expanded, but plant-related costs and financial items compressed profitability.

Production capacity comes first

Promopharm operates two manufacturing plants in Morocco and produces and markets pharmaceutical products, according to its corporate website. The company reported 409 employees on that page, linking the earnings story to a manufacturing base that is expanding before the new injectable unit reaches full commercial contribution.

Promopharm SA is listed on the Casablanca Stock Exchange under ticker PRO.MA and operates in Health Technology, according to MyStocks. The next test for the stock is whether revenue growth can absorb depreciation, research costs and foreign-exchange effects in subsequent reporting periods.

Market context stays measured

Promopharm's MAD 1,480.00 quotation on October 13, 2026 stood below the MAD 1,589.00 52-week high and above the MAD 1,223.00 low. That 29.00 percent spread between the yearly low and high highlights the limited trading depth around a stock whose reported earnings have recently moved much more sharply than its sales.

Market report Latest market reports.

More news and analyses on Promopharm stock